CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Patheon NV is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Patheon NV
Herengracht 483
Phone: +31 206223243p:+31 206223243 AMSTERDAM, 1017 BT  Netherlands
This company was Merged or Acquired on 8/29/2017.
This company ceased filing statements with the SEC on 9/13/2017.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
4/30/201710/31/2016YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8742 Management consulting services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Paul S.Levy 69
Chief Executive Officer, Director James C.Mullen 58 2/1/2011 2/1/2011
Chief Financial Officer, Executive Vice President Stuart R.Grant 60 2/1/2012 1/1/2012
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Banner Pharmacaps Inc.
CEPH International Corporation
DPI Newco LLC
42 additional Business Names available in full report.

General Information
Stock Exchange: NYSE
Federal Tax Id: 981153534


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023